Company profile
Lyell Immunopharma, Inc.
NASDAQ: LYEL · Healthcare · Biotechnology
#1095 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
31DFH 27DQ 40GM 15SS 54
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$31.0k
Rev growth YoY (TTM)
-52.3%
Net income (FY)
-$274.4M
Employees
161
as of 2026-08-12
Market cap
$364.6M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$36.0k$36.0k2025
Net income-$274.4M-$274.4M2025
Operating income-$269.4M-$269.4M2025
Total assets$340.1M$340.1M2025
Liabilities$91.8M$91.8M2025
Equity$248.2M$248.2M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Lyell Immunopharma, Inc.’s revenue?
Lyell Immunopharma, Inc. booked $36.0k in FY2025 revenue, contracting 41% year over year — slower than 79% of Healthcare companies we track, at a -762355.6% net margin.
Peers · Healthcare
Hi-Great Group Holding Company25DGridAI Technologies Corp.30DForte Biosciences, Inc.26DFrélii, Inc.——NanoLogix, Inc.——Mountain Valley MD Holdings Inc.——Neighbors
San Mateo →Key facts
CEOLynn Seely
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: LYEL
Employees161
IPO date2021-06-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.